Revelation Biosciences Inc (REVB) - Net Assets
Based on the latest financial reports, Revelation Biosciences Inc (REVB) has net assets worth $11.00 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($12.86 Million) and total liabilities ($1.85 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check REVB cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $11.00 Million |
| % of Total Assets | 85.58% |
| Annual Growth Rate | -36.07% |
| 5-Year Change | 38.01% |
| 10-Year Change | N/A |
| Growth Volatility | 218.04 |
Revelation Biosciences Inc - Net Assets Trend (2016–2024)
This chart illustrates how Revelation Biosciences Inc's net assets have evolved over time, based on quarterly financial data. Also explore REVB asset base for the complete picture of this company's asset base.
Annual Net Assets for Revelation Biosciences Inc (2016–2024)
The table below shows the annual net assets of Revelation Biosciences Inc from 2016 to 2024. For live valuation and market cap data, see Revelation Biosciences Inc market cap and net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $4.71 Million | -29.17% |
| 2023-12-31 | $6.65 Million | +531.64% |
| 2022-12-31 | $1.05 Million | +1158.06% |
| 2021-12-31 | $-99.47K | -102.92% |
| 2020-12-31 | $3.41 Million | +93877.46% |
| 2019-12-31 | $-3.64K | -100.00% |
| 2018-12-31 | $264.89 Million | +40.69% |
| 2017-12-31 | $188.28 Million | +11.57% |
| 2016-12-31 | $168.76 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Revelation Biosciences Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 315.6% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $522.00 | 0.01% |
| Other Components | $45.21 Million | 960.28% |
| Total Equity | $4.71 Million | 100.00% |
Revelation Biosciences Inc Competitors by Market Cap
The table below lists competitors of Revelation Biosciences Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Damon Inc. Common Stock
NASDAQ:DMN
|
$2.94 Million |
|
Rocky Mountain Liquor Inc
V:RUM
|
$2.94 Million |
|
Eastern Resources Ltd
AU:EFE
|
$2.94 Million |
|
Timah Resources Ltd
AU:TML
|
$2.95 Million |
|
Next 15 Group PLC
LSE:NFG
|
$2.94 Million |
|
Netcapital Inc
NASDAQ:NCPL
|
$2.94 Million |
|
Mid Wynd International Investment Trust plc
LSE:MWY
|
$2.93 Million |
|
NetJobs Group AB
ST:NJOB
|
$2.93 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Revelation Biosciences Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 6,647,715 to 4,708,382, a change of -1,939,333 (-29.2%).
- Net loss of 15,038,536 reduced equity.
- New share issuances of 5,417,053 increased equity.
- Other factors increased equity by 7,682,150.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-15.04 Million | -319.4% |
| Share Issuances | $5.42 Million | +115.05% |
| Other Changes | $7.68 Million | +163.16% |
| Total Change | $- | -29.17% |
Book Value vs Market Value Analysis
This analysis compares Revelation Biosciences Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.04x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $-6.72 | $1.12 | x |
| 2020-12-31 | $18899.92 | $1.12 | x |
| 2021-12-31 | $-169.29 | $1.12 | x |
| 2022-12-31 | $58.57 | $1.12 | x |
| 2023-12-31 | $465.20 | $1.12 | x |
| 2024-12-31 | $27.45 | $1.12 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Revelation Biosciences Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -319.40%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.41x
- Recent ROE (-319.40%) is below the historical average (-147.77%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 5.20% | 17.98% | 0.03x | 11.22x | $-8.10 Million |
| 2017 | 8.64% | 21.99% | 0.04x | 11.15x | $-2.56 Million |
| 2018 | 10.43% | 32.46% | 0.03x | 9.27x | $1.14 Million |
| 2019 | 0.00% | 0.00% | 4226.19x | 0.00x | $-3.27K |
| 2020 | -4.00% | 0.00% | 0.00x | 1.35x | $-477.57K |
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | $-11.98 Million |
| 2022 | -1028.98% | 0.00% | 0.00x | 5.23x | $-10.93 Million |
| 2023 | -1.81% | 0.00% | 0.00x | 1.84x | $-785.03K |
| 2024 | -319.40% | 0.00% | 0.00x | 1.41x | $-15.51 Million |
Industry Comparison
This section compares Revelation Biosciences Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Revelation Biosciences Inc (REVB) | $11.00 Million | 5.20% | 0.17x | $2.94 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About Revelation Biosciences Inc
Revelation Biosciences, Inc. operates as a clinical-stage biopharmaceutical company that focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treat… Read more